RUA Life Sciences (GB:RUA)
LSE:RUA
Want to see GB:RUA full AI Analyst Report?
RUA Stock Chart & Stats
14.00 p
-0.50 p(-3.85%)
At close: 4:00 PM EST
14.00 p
-0.50 p(-3.85%)
Day’s Range― - ―
52-Week Range10.42 p - 26.80 p
Previous CloseN/A
Volume378.53K
Average Volume (3M)148.53K
Market Cap
£12.10M
Enterprise Value10.21M
Total Cash (Recent Filing)£3.25M
Total Debt (Recent Filing)£794.00K
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Jul 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding62,060,272
10 Day Avg. Volume90,619
30 Day Avg. Volume148,527
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.98
Price to Sales (P/S)1.57
P/FCF Ratio-23.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£7.10M
Bulls Say, Bears Say
Bulls Say
High Gross Margin And Scaled RevenueSustained revenue growth with a ~69% gross margin indicates product-market fit and structural unit economics. High gross margin provides room to cover fixed R&D and SG&A as topline scales, improving the probability of durable operating leverage and eventual profitability.
Conservative Balance Sheet With Low LeverageVery low debt-to-equity gives the company financial flexibility to fund growth or weather extended losses without immediate solvency risk. A conservative capital structure reduces refinancing pressure and supports longer runway for R&D, commercialization and strategic investments.
Dual Business Model: Product Dev And Contract ManufacturingOperating both product development and contract manufacturing diversifies revenue streams and customer exposure. Contract services can provide recurring, less cyclical income while product commercialization offers higher margin upside, a structural advantage for long-term revenue stability.
Bears Say
Persistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flow forces reliance on external funding to support operations and growth. Continued cash burn increases dilution risk or constrains investment in scale-up, potentially delaying a self‑funding profile and heightening financing vulnerability.
Operating Losses And Negative MarginsDespite strong gross margins, the company reports negative EBIT (~-18.5%) and a small net loss, meaning fixed costs and operating expenses still outstrip core profit. Until operating leverage is reached, sustainable profitability and returns on equity remain uncertain for investors.
Small Absolute Scale Limits Economies And FlexibilityAbsolute revenue remains modest, limiting ability to amortize fixed R&D and manufacturing overheads. Small scale can slow margin expansion, lengthen the path to break-even, and increase sensitivity to single-customer or contract variability, pressuring longer-term resilience.
RUA Life Sciences News
RUA FAQ
What was RUA Life Sciences’s price range in the past 12 months?
RUA Life Sciences lowest share price was 10.42 p and its highest was 26.80 p in the past 12 months.
What is RUA Life Sciences’s market cap?
RUA Life Sciences’s market cap is £12.10M.
When is RUA Life Sciences’s upcoming earnings report date?
RUA Life Sciences’s upcoming earnings report date is Jul 13, 2026 which is in 25 days.
How were RUA Life Sciences’s earnings last quarter?
RUA Life Sciences released its earnings results on Jan 30, 2026. The company reported 0.008 p earnings per share for the quarter, beating the consensus estimate of N/A by 0.008 p.
Is RUA Life Sciences overvalued?
According to Wall Street analysts RUA Life Sciences’s price is currently Overvalued.
Does RUA Life Sciences pay dividends?
RUA Life Sciences does not currently pay dividends.
What is RUA Life Sciences’s EPS estimate?
RUA Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RUA Life Sciences have?
RUA Life Sciences has 62,060,272 shares outstanding.
What happened to RUA Life Sciences’s price movement after its last earnings report?
RUA Life Sciences reported an EPS of 0.008 p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -7.937%.
Which hedge fund is a major shareholder of RUA Life Sciences?
Currently, no hedge funds are holding shares in GB:RUA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RUA Life Sciences
RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's operations encompass serving as a contract partner for the development and manufacturing of medical devices. Furthermore, it licenses its proprietary Elast-Eon and ECSil implantable co-polymers, which are integrated into cardiac and urological applications, including pacing leads, cardiac cannulae, and stent devices. RUA also grants licenses for its reaction injection molding technology, crucial for crafting high-precision medical device components. The firm is actively engaged in developing innovative bore polymer-sealed grafts, advanced soft tissue patches, and novel three-leaflet polymeric heart valves. Established in 1996 and based in Irvine, United Kingdom, the company adopted its current name, RUA Life Sciences plc, in June 2020, having previously been known as AorTech International plc.
Technical Analysis
Creo Medical
―
Genedrive
―
Inspiration Healthcare
―
OptiBiotix Health
―
Surgical Innovations
―
Options Prices
Currently, No data available
---